Takeda announces positive topline results from phase 2 study evaluating mezagitamab (tak-079), a potential best-in-class anti-cd38 monoclonal antibody, for primary immune thrombocytopenia

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive topline results from a phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (tak-079) in patients with persistent or chronic primary immune thrombocytopenia (itp). mezagitamab is a fully human immunoglobulin igg1 monoclonal antibody (mab) with high affinity for cd38 expressing cells (including plasmablasts, plasma cells, nat.
TAK Ratings Summary
TAK Quant Ranking